Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

被引:123
作者
Hebert, MF
Smith, HE
Marbury, TC
Swan, SK
Smith, WB
Townsend, RW
Buell, D
Keirns, J
Bekersky, I
机构
[1] Univ Washington, Dept Pharm, Seattle, WA 98195 USA
[2] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
[3] Orlando Clin Res Ctr, Orlando, FL USA
[4] DoVita Clin Res & Hennepin Cty Med Ctr, Minneapolis, MN USA
[5] New Orleans Ctr Clin Res, New Orleans, LA USA
[6] Fujisawa Healthcare Inc, Deerfield, IL USA
关键词
micafungin; liver disease; renal disease; pharmacokinetics;
D O I
10.1177/0091270005279580
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Micofungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferose. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance <30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micofungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 +/- 19 mu g center dot h/mL vs 125.9 +/- 26.4 mu g center dot h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 +/- 1.7mL/h/kg vs 9.8 +/- 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.
引用
收藏
页码:1145 / 1152
页数:8
相关论文
共 21 条
[1]  
AGARWAL DP, 1983, DRUG ALCOHOL DEPEN, V12, P85
[2]   Leukocyte arylsulfatase a activity in patients with alcohol-related cirrhosis [J].
Alvarez-Leal, M ;
Contreras-Hernández, D ;
Chávez, A ;
Diaz-Contreras, JA ;
Careaga-Olivares, J ;
Zúñiga-Charles, MA ;
Reynoso, MC ;
Hernandez-Téllez, A .
AMERICAN JOURNAL OF HUMAN BIOLOGY, 2001, 13 (03) :297-300
[3]   NONCOMPARTMENTAL DETERMINATION OF THE STEADY-STATE VOLUME OF DISTRIBUTION [J].
BENET, LZ ;
GALEAZZI, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1071-1074
[4]   New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease [J].
Bonifati, V ;
Meco, G .
PHARMACOLOGY & THERAPEUTICS, 1999, 81 (01) :1-36
[5]   HUMAN LIVER CATECHOL-O-METHYLTRANSFERASE PHARMACOGENETICS [J].
BOUDIKOVA, B ;
SZUMLANSKI, C ;
MAIDAK, B ;
WEINSHILBOUM, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (04) :381-389
[6]   PLATELET PHENOL SULFOTRANSFERASE AND ERYTHROCYTE CATECHOL-O-METHYLTRANSFERASE ACTIVITIES - CORRELATION WITH METHYLDOPA METABOLISM [J].
CAMPBELL, NRC ;
DUNNETTE, JH ;
MWALUKO, G ;
VANLOON, J ;
WEINSHILBOUM, RM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (01) :55-63
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   INCREASED HEPATIC LYSOSOMAL ACTIVITY IN BILIARY-CIRRHOSIS ORIGINATES FROM HEPATOCYTES RATHER THAN FROM MACROPHAGES [J].
DUFOUR, JF ;
ZIMMERMANN, A ;
REICHEN, J .
JOURNAL OF HEPATOLOGY, 1994, 20 (04) :524-530
[9]  
GULDBERG HC, 1975, PHARMACOL REV, V27, P135
[10]   Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders [J].
Lachman, HM ;
Papolos, DF ;
Saito, T ;
Yu, YM ;
Szumlanski, CL ;
Weinshilboum, RM .
PHARMACOGENETICS, 1996, 6 (03) :243-250